BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34191670)

  • 1. Ultra-central lung tumors: safety and efficacy of protracted stereotactic body radiotherapy.
    Lodeweges JE; van Rossum PSN; Bartels MMTJ; van Lindert ASR; Pomp J; Peters M; Verhoeff JJC
    Acta Oncol; 2021 Aug; 60(8):1061-1068. PubMed ID: 34191670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late Toxicity and Long-Term Local Control in Patients With Ultra-Central Lung Tumours Treated by Intensity-Modulated Radiotherapy-Based Stereotactic Ablative Body Radiotherapy With Homogenous Dose Prescription.
    Mihai AM; Armstrong PJ; Hickey D; Milano MT; Dunne M; Healy K; Thirion P; Heron DE; ElBeltagi N; Armstrong JG
    Clin Oncol (R Coll Radiol); 2021 Oct; 33(10):627-637. PubMed ID: 34092462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation.
    Repka MC; Aghdam N; Kataria SK; Campbell L; Suy S; Collins SP; Anderson E; Lischalk JW; Collins BT
    Radiat Oncol; 2017 Oct; 12(1):162. PubMed ID: 29052514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic body radiotherapy for Ultra-Central lung Tumors: A systematic review and Meta-Analysis and International Stereotactic Radiosurgery Society practice guidelines.
    Yan M; Louie AV; Kotecha R; Ashfaq Ahmed M; Zhang Z; Guckenberger M; Kim MS; Lo SS; Scorsetti M; Tree AC; Sahgal A; Slotman BJ
    Lung Cancer; 2023 Aug; 182():107281. PubMed ID: 37393758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.
    Meng MB; Wang HH; Zaorsky NG; Sun BS; Zhu L; Song YC; Li FT; Dong Y; Wang JS; Chen HM; Yu XY; Yuan ZY
    Cancer Sci; 2019 Nov; 110(11):3553-3564. PubMed ID: 31464032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer.
    Cong Y; Sun B; Wang J; Meng X; Xuan L; Zhang J; Liu J; Shen G; Wu S
    Thorac Cancer; 2019 Jul; 10(7):1567-1575. PubMed ID: 31187604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
    Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
    Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultra-central Thoracic Re-irradiation Using 10-fraction Stereotactic Body Radiotherapy for Recurrent Non-small-cell Lung Cancer Tumors: Preliminary Toxicity and Efficacy Outcomes.
    Sood S; Ganju R; Shen X; Napel MT; Wang F
    Clin Lung Cancer; 2021 May; 22(3):e301-e312. PubMed ID: 33132058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy.
    Duijm M; van der Voort van Zyp NC; Granton PV; van de Vaart P; Mast ME; Oomen-de Hoop E; Hoogeman MS; Nuyttens JJ
    Acta Oncol; 2020 Jul; 59(7):809-817. PubMed ID: 32286140
    [No Abstract]   [Full Text] [Related]  

  • 10. Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus.
    Song SY; Choi W; Shin SS; Lee SW; Ahn SD; Kim JH; Je HU; Park CI; Lee JS; Choi EK
    Lung Cancer; 2009 Oct; 66(1):89-93. PubMed ID: 19168260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Prospective Phase 2 Study Evaluating Safety and Efficacy of Combining Stereotactic Body Radiation Therapy With Heat-based Ablation for Centrally Located Lung Tumors.
    Sandler KA; Abtin F; Suh R; Cook RR; Felix C; Lee JM; Garon EB; Wu J; Luterstein EM; Agazaryan N; Tenn SE; Lee C; Steinberg ML; Lee P
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):564-573. PubMed ID: 29893274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HILUS-Trial-a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy.
    Lindberg K; Grozman V; Karlsson K; Lindberg S; Lax I; Wersäll P; Persson GF; Josipovic M; Khalil AA; Moeller DS; Nyman J; Drugge N; Bergström P; Olofsson J; Rogg LV; Ramberg C; Kristiansen C; Jeppesen SS; Nielsen TB; Lödén B; Rosenbrand HO; Engelholm S; Haraldsson A; Billiet C; Lewensohn R
    J Thorac Oncol; 2021 Jul; 16(7):1200-1210. PubMed ID: 33823286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiotherapy for central lung tumors.
    Rowe BP; Boffa DJ; Wilson LD; Kim AW; Detterbeck FC; Decker RH
    J Thorac Oncol; 2012 Sep; 7(9):1394-9. PubMed ID: 22843088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy.
    Modh A; Rimner A; Williams E; Foster A; Shah M; Shi W; Zhang Z; Gelblum DY; Rosenzweig KE; Yorke ED; Jackson A; Wu AJ
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1168-76. PubMed ID: 25303891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity and efficacy of stereotactic body radiotherapy for ultra-central lung tumours: a single institution real life experience.
    Guillaume E; Tanguy R; Ayadi M; Claude L; Sotton S; Moncharmont C; Magné N; Martel-Lafay I
    Br J Radiol; 2022 Jan; 95(1129):20210533. PubMed ID: 34797724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Effectiveness of Stereotactic Ablative Radiotherapy for Ultra-Central Lung Lesions: A Systematic Review.
    Chen H; Laba JM; Zayed S; Boldt RG; Palma DA; Louie AV
    J Thorac Oncol; 2019 Aug; 14(8):1332-1342. PubMed ID: 31075543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Control and Toxicity for Common Stereotactic Body Radiation Therapy Dose-Fractionation Regimens in Stage I Non-Small Cell Lung Cancer.
    Stephans KL; Woody NM; Reddy CA; Varley M; Magnelli A; Zhuang T; Qi P; Videtic GMM
    Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):462-469. PubMed ID: 29353658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.
    Steber CR; Hughes RT; Soike MH; Jacobson T; Helis CA; Farris JC; Farris MK
    Clin Lung Cancer; 2021 Jan; 22(1):e122-e131. PubMed ID: 33046359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving geometric sparing and therapeutic effectiveness of lung SBRT for central and ultra-central tumors.
    Fakir H; Randhawa GK; Millman B; Laba J
    Med Dosim; 2021 Winter; 46(4):398-403. PubMed ID: 34172369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity and Efficacy of Stereotactic Ablative Body Radiotherapy for Moderately Central Non-small Cell Lung Cancers Using 50 Gy in Five Fractions.
    Rulach R; McLoone P; Lumsden G; McKay S; MacLaren V; Macphee J; Moore K; Omand M; Sproule M; Currie S; Aitken A; Ferguson R; Valentine R; Houston P; Harrow S; Hicks J
    Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):250-258. PubMed ID: 31607611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.